Journal of the National Comprehensive Cancer Network · 2018 · 316 citations · 194 references
MedicineOncologyPathologyImmunotherapySurgical OncologyTumor PathologyCancer ImmunotherapyCancer StagingImmune Checkpoint RegulationMalignant NeoplasmsMerkel Cell CarcinomaRadiation TherapyCheckpoint Modulation In CancerImmune Checkpoint Combination TherapyMerkel Cell Carcinoma HistopathologyMerkel Cell Carcinoma ImmunotherapyMerkel Cell Carcinoma StagingMerkel Cell Carcinoma TherapyNodal Basin SurgeryStaging Of Advanced Disease
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.
194
Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
Huichen Feng, Masahiro Shuda, Yuan Chang et al. · Science · 2008 · 3.2K citations · Full text
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem, Shailender Bhatia, Evan J. Lipson et al. · New England Journal of Medicine · 2016 · 1.2K citations · Full text
Medicine, Dermatology, Oncology +17
Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.
R. Moll, A D Lowe, Jürgen Laufer et al. · PubMed · 1992 · 813 citations